This selective upregulation identifies Brd4 as a key mediator of microglial responses to amyloid pathology, underscoring its potential as a promising therapeutic target for neuroinflammation and Alzheimer’s disease (AD). This evidence concerns the gene BRD4 and amyloidosis.